A new study being presented at MAD-ID looked at this class of therapies vs oral penicillins and found the former to be non-inferior to the latter.
Image credit: Towfiqu Barbhuiya, Pexels
In a study being presented at MAD-ID, oral cephalosporins were found to be non-inferior to oral penicillins for the treatment of gram-negative Enterobacterales bloodstream infections.
“Step-down therapy with oral cephalosporins was non-inferior to step-down with oral penicillins for treatment failure (7.1% vs. 7.1%; 95% CI [-0.064, 0.064], p = 0.002),” the investigators wrote. “No significant differences were found for antibiotic-associated adverse events, CDI, or microbiological failure within 30 days.”
This was a retrospective observational study conducted from January 2022 through October 2024. The study aimed to evaluate the safety and efficacy of oral cephalosporins vs oral penicillins as step-down therapy.
The primary outcome was treatment failure defined as infection-related readmission or mortality, documented treatment failure in an outpatient office visit, or change in antibiotic due to documented clinical worsening within 30 days. A pre-specified non-inferiority margin of 10% was used.
Secondary outcomes included antibiotic-associated adverse events, Clostridioides difficile infection, and microbiological failure within 30 days.
"No significant differences were found for antibiotic-associated adverse events, CDI, or microbiological failure within 30 days. In a pre-specified subgroup analysis of < 10 and >10 days of therapy, there was no significant difference in treatment failure despite a higher number of treatment failure in patients receiving >10 days of therapy (8.2% vs. 2.1%, p=0.215)," the investigators wrote.
A total of 280 adult patients were included (140 in each group). Compared to the penicillin cohort, more patients in the cephalosporin group were female (61.4% vs. 49.3%, p = 0.041), had a urinary source of infection (87.9% vs. 62.1%), and had urinary abnormalities (40% vs. 28.6%).
Patients in both groups received a median of 5 days of IV antibiotics prior to step-down to oral therapy, with no difference in the median total duration of therapy (14 days vs. 15 days).
Interestingly, the cephalosporin group had fewer infectious diseases consults (18.6% vs. 36.4%).
Previous studies have shown that oral antibiotic step-down therapy for the treatment of gram-negative bloodstream infections is non-inferior to a full course of intravenous therapy. However, most studies have included only highly bioavailable antibiotics. While comparisons among fluoroquinolones, sulfamethoxazole-trimethoprim, and beta-lactams have shown similar outcomes, beta-lactam treatment groups have been small and primarily composed of penicillins.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.